share_log

Wedbush Upgrades CytomX Therapeutics to Outperform, Raises Price Target to $3

Benzinga ·  Nov 8, 2023 13:59

Wedbush analyst Robert Driscoll upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Outperform and raises the price target from $2 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment